Abivax S.A. (ABVX) Stock Forecast Nov. 11, 2026
Analysis updated on Nov. 11, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Abivax S.A. (ABVX) stock forecast summary
Our AI scores Abivax S.A. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Abivax S.A. is a mid-cap company with a market capitalization of $7.07B. It ranks number 44 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ABVX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -28.0%, measured on 223 forecast dates between 2025-03-26 and 2026-08-13 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 265 forecast dates between 2025-03-26 and 2026-10-12. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +6.4%, buy ≥ +4.3%, sell < +2.1%, strong sell < +0.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-10 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ABVX included.
ABVX price chart and AI forecast
How ABVX ranks among 4243 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Abivax S.A. (ABVX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric. Statement values were filed in EUR and are shown converted to USD (flows at the trailing twelve-month average rate, balances at the balance-sheet date rate).
Valuation & Market
| Metric | ABVX | Rank |
|---|---|---|
| Market Cap | $7.07B | 44/60 |
| EPS | $-9.65 | – |
| FCF/Share | $-5.76 | – |
Profitability & Margins
| Metric | ABVX | Rank |
|---|---|---|
| ROE | -129.7% | 34/39 |
| ROA | -101.0% | 42/43 |
| ROIC | -80.7% | 43/46 |
| Tax Rate | -1.0% | – |
Financial Health
| Metric | ABVX | Rank |
|---|---|---|
| Current Ratio | 8.75x | 11/58 |
| Financial Leverage | 1.28x | 34/47 |
| Working Capital | $574M | 38/58 |
Cash Flow
| Metric | ABVX | Rank |
|---|---|---|
| Operating Cash Flow | -$452M | 56/60 |
| Free Cash Flow | -$452M | 47/51 |
| Capital Spending | -$340K | 4/51 |
Income Statement
| Metric | ABVX | Rank |
|---|---|---|
| Operating Income | -$476M | 47/52 |
| Net Income | -$669M | 43/47 |
| R&D Expense | $353M | 36/59 |
Dividend & Shareholder Information
| Metric | ABVX | Rank |
|---|---|---|
| Shares Outstanding | 79M | – |
Balance Sheet Highlights (USD millions, converted from EUR)
| Total Current Assets | $648M | |
| Cash & Short-term Investments | $607M | |
| Short-term Debt | $30M |
ABVX quarterly financials and insider trading
Abivax S.A. (ABVX) industry peers
Companies classified under the same SEC industry code as Abivax S.A. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ABVX Abivax S.A. | $7.07B | |
| LLY Eli Lilly & Co | $1.35T | |
| JNJ Johnson & Johnson | $675.92B | |
| ABBV Abbvie Inc. | $519.34B | |
| MRK Merck & Co., Inc. | $365.26B | |
| NVS Novartis Ag | $311.52B | |
| AZN Astrazeneca Plc | $289.48B | |
| ABT Abbott Laboratories | $192.07B | |
| NVO Novo Nordisk A S | $180.87B | |
| PFE Pfizer Inc | $166.60B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $139.62B | |
| BMY Bristol Myers Squibb Co | $128.37B | |
| SNY Sanofi | $118.63B | |
| GSK Gsk Plc | $103.35B | |
| REGN Regeneron Pharmaceuticals, Inc. | $94.71B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.88B | |
| TEVA Teva Pharmaceutical Industries Ltd | $50.07B | |
| ONC Beone Medicines Ltd. | $48.20B | |
| GMAB Genmab A/S | $34.78B | |
| ZTS Zoetis Inc. | $34.02B | |
| RPRX Royalty Pharma Plc | $29.45B | |
| ROIV Roivant Sciences Ltd. | $29.38B | |
| INSM Insmed Inc | $26.21B | |
| UTHR United Therapeutics Corp | $24.98B | |
| VTRS Viatris Inc | $23.53B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.31B | |
| ASND Ascendis Pharma A/S | $16.85B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.93B | |
| BBIO Bridgebio Pharma, Inc. | $15.32B | |
| SMMT Summit Therapeutics Inc. | $14.23B | |
| ELAN Elanco Animal Health Inc | $13.37B | |
| RDY Dr Reddys Laboratories Ltd | $12.56B | |
| BMRN Biomarin Pharmaceutical Inc | $11.06B | |
| TGTX Tg Therapeutics, Inc. | $10.06B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.99B | |
| SYRE Spyre Therapeutics, Inc. | $9.61B | |
| PRAX Praxis Precision Medicines, Inc. | $9.30B | |
| PTGX Protagonist Therapeutics, Inc | $8.79B | |
| CORT Corcept Therapeutics Inc | $7.93B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.85B | |
| CYTK Cytokinetics Inc | $7.81B | |
| ALKS Alkermes Plc. | $7.80B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.47B | |
| AXSM Axsome Therapeutics, Inc. | $7.38B | |
| ORKA Oruka Therapeutics, Inc. | $6.92B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.92B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.83B | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | |
| MANE Veradermics, Inc | $6.20B | |
| BLTE Belite Bio, Inc | $6.16B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.13B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| COGT Cogent Biosciences, Inc. | $5.49B | |
| PTCT Ptc Therapeutics, Inc. | $5.43B | |
| ERAS Erasca, Inc. | $5.41B | |
| EWTX Edgewise Therapeutics, Inc. | $5.05B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.97B | |
| IONS Ionis Pharmaceuticals Inc | $4.68B | |
| TVTX Travere Therapeutics, Inc. | $4.62B | |
| LQDA Liquidia Corp | $4.60B |
Where ABVX sits on the market map
Abivax S.A. (ABVX) stock news
Loading...
Abivax S.A. (ABVX) stock forecast FAQ
What is the Abivax S.A. (ABVX) stock forecast?
Our AI scores Abivax S.A. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Abivax S.A. stock predictions?
For ABVX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -28.0%, measured on 223 forecast dates between 2025-03-26 and 2026-08-13 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 9.0%, measured on 265 forecast dates between 2025-03-26 and 2026-10-12. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Abivax S.A. forecasts updated?
Abivax S.A. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 11, 2026.
Which companies are Abivax S.A.'s industry peers?
60 issuers in our coverage, ABVX included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.